Fig.7

β-arrestin 2 depletion reverses roles of fluoxetine in depressive-like behaviors and A1 astrocyte reactivity in CMS mice. A Sucrose preference percentage of WT and β-arrestin 2 knockout mice during 10 week treatment. B Immobility time of mice in TST and FST. C, D Expression of C3 on astrocyte in the hippocampus of WT and β-arrestin 2^−/− mice with or without fluoxetine treatment. E, F Protein levels of C3 in the hippocampus. G Levels of A1-special genes in the hippocampus. Scar bar, 20 μm in C. Quantitative data are mean ± s.e. Data were analyzed using two-way ANOVA, then combined with Tukey’s multiple comparison to assess the differences between groups. A, B: n = 8 (A, B-FST), n = 9 (B-TST) WT CON with saline; n = 8 WT CON with FLX; n = 8 (A), n = 10 (B) WT CMS with saline; n = 8 (B-FST), n = 9 (A, B-TST) WT CMS with FLX; n = 8 (A), n = 9 (B-TST), n = 10 (B-FST) β-arrestin 2^−/− CON with saline; n = 8 (A, B-FST), n = 10 (B-TST) β-arrestin 2^−/− CON with FLX; n = 8 (A, B-FST), n = 9 (B-TST) β-arrestin 2^−/− CMS with saline; n = 8 β-arrestin 2^−/− CMS with FLX; C-G: n = 4 per group; biologically independent animals. A: ***P < 0.001 vs respective Control mice treated with saline; ^###P < 0.001 vs WT CMS mice treated with saline; ^$$P < 0.01vs WT CMS mice treated with fluoxetine; B, D, F and G: ***P < 0.001 vs respective Control mice treated with saline; ^###P < 0.001 vs WT CMS mice treated with saline; ^$P < 0.05, ^$$$P < 0.001